Is it safe to withdraw etanercept in established rheumatoid arthritis after low disease activity achievement?
Rheumatoid arthritis (RA) is an immunologically driven chronic condition characterized not only by persistent joint inflammation (synovitis) but also by systemic inflammation .
Uncontrolled active RA produces disability and a reduction of the health-related quality of life that result in loss of work and high medical and social costs . The impact of RA on patients and society justifies treatment with biologics , expensive drugs that are not free from complications and adverse events, even severe .
The target of treatment in RA is achievement of low disease activity or remission . It is yet to be clarified whether low disease activity or remission can be also sustained, not only by maintaining the recommended therapy but also by reducing or discontinuing the biologic treatment. In fact, a reduction or withdrawal of such treatment could imply a great amount of financial saving for the National Health Systems.
Although there are many observational studies regarding w ...
- Scott DL, Wolfe F, Huizinga TW (2009) Rheumatoid arthritis. Lancet 376:1094–1108 CrossRef
- Furneri G, Mantovani LG, Belisari A, Mosca M, Cristiani M, Bellelli S, Cortesi PA, Turchetti G (2012) Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 30:S72–S84
- Ruderman EM (2012) Overview of safety of non-biologic and biologic DMARDs. Rheumatology 51:vi37–vi43 CrossRef
- Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O’Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64:625–639 CrossRef
- Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 381:918–929 CrossRef
- Is it safe to withdraw etanercept in established rheumatoid arthritis after low disease activity achievement?
Internal and Emergency Medicine
Volume 9, Issue 2 , pp 223-224
- Cover Date
- Print ISSN
- Online ISSN
- Springer Milan
- Additional Links